VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | GvHD in MM patients treated w/ dara post-alloHCT

Joshua Richter, Mount Sinai Medical Center, New York, NY, discusses a multicenter retrospective study which evaluated the incidence of graft-versus-host disease (GvHD) in 34 patients with relapsed multiple myeloma treated with daratumumab after allogeneic hematopoietic cell transplantation (allo-HCT). Dr Richter and his colleagues concluded that the incidence of GvHD after daratumumab was low and did not result in increased exacerbation of GvHD in patients with a history of GvHD. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter